Date: 2016-01-07
Type of information: Nomination
Compound:
Company: Glycotope (Germany)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On January 7, 2016, Glycotope announced the appointment of Paul G Higham as its new Chief Executive Officer (CEO), effective immediately. Paul G Higham was Chief Executive Officer of Immatics Biotechnologies from August 2008 to August 2015. During his time at the Company, Immatics grew and successfully developed into a leading cancer immunotherapy company with exceptional technologies, capabilities and growth opportunities. Previously, he served as Director Commercial Development at Ark Therapeutics Group plc where he was responsible for commercial strategy and all business development activities. In addition, he was in charge of establishing the operations and gene-based medicine production facilities of Ark Therapeutics in Finland. Before joining Ark Therapeutics in 2001, Paul G Higham worked as International Commercial Vice President for GI, Metabolic and Pain at GlaxoWellcome plc, where he was responsible for all aspects of international commercial strategy. Prior to that he held various sales and marketing positions with increasing responsibilities with Bayer AG becoming General Manager of Bayer Pharmaceuticals for Sweden and Denmark. He holds an honours degree in Applied Biology.
Financial terms:
Latest news:
